Solution Group Bhd’s (SGB) wholly-owned subsidiary Solution Biologics Sdn Bhd (Solbio) has signed a finished product and a bulk product agreement today with CanSino Biologics Inc for the supply of the Recombinant Ad5-nCoV vaccine for use against Covid-19.

In a statement, the group said the finished product agreement allows Solbio to purchase and CanSino to supply the finish product vaccine for emergency use in Malaysia...